Next, we analyzed the persistence of transferred T-cells in the peripheral blood 3 weeks following adoptive transfer and detected higher numbers of CD4+ and CD8+ T cells in mice treated with both the C4 and MOv19 CAR T cells groups compared with the UNT and CD19-27z CAR T cells treatment group (Figure 6D), suggesting that tumor antigen recognition drives the survival of the adoptively transferred T cells in vivo. Here, CD8A is linked to neoplasm.